NEW YORK (GenomeWeb News) – Danaher said today that its revenues in the fourth quarter rose 6 percent year over year with its Life Sciences & Diagnostics segment leading the way.

For the three months ended Dec. 31, 2013, the company posted revenues of $5.27 billion, up from $4.98 billion in Q4 2012, and beating the consensus Wall Street estimate of $5.20 billion.

Danaher's profit for the quarter was up to $789.3 million, or $1.11 per share, from $630.4 million, or $0.89 per share, in Q4 2012, besting analyst estimates of $0.95 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.